Oncolytic Virus Competitive Landscape Clinical Trials, Growth, and Key Companies | Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics

Oncolytic Virus Competitive Landscape Clinical Trials, Growth, and Key Companies | Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics

June 07
14:07 2023
Oncolytic Virus Competitive Landscape Clinical Trials, Growth, and Key Companies | Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics
DelveInsight Business Research LLP
DelveInsight’s “Oncolytic Virus – Competitive landscape, 2022” report provides comprehensive insights about 150+ companies and 175+ drugs in Oncolytic Virus Competitive landscape

Key Takeaways from the Complicated Skin And Soft Tissue Infections Pipeline Report

  • Over 150+ Companies and 175 + Pipeline Drugs for Complicated Skin And Soft Tissue Infections are in various stages of development, and their anticipated acceptance in the Complicated Skin And Soft Tissue Infections market would significantly increase market revenue. 

  • Leading Complicated Skin And Soft Tissue Infections companies developing novel drug candidates to improve the Complicated Skin And Soft Tissue Infections treatment landscape includes Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech and others.

  • Promising Complicated Skin And Soft Tissue Infections pipeline therapies in various stages of development include Pexa-Vec and many others.

Oncolytic Virus  Infections Overview

Oncolytic viruses (OVs) are organisms able to identify, infect, and lyse different cells in the tumor environment, aiming to stabilize and decrease the tumor progression. They are able to infect abnormal cells through specific targets, such as nuclear transcription factors and among them human telomerase reverse transcriptase, prostate specific antigen, cyclooxygenase-2, osteocalcin, and surface markers as prostate-specific membrane antigen, folate receptor, CD20, endothelial growth factor receptor, and Her2/neu, which are substances produced by the tumor cells. Furthermore, the deletion of pathogenic viral genes in the laboratory in order to increase the selectivity to the tumor cells and decrease the aggressiveness of the OVs to normal tissues is also possible. 

Complicated Skin And Soft Tissue Infections Pipeline Therapies and Key Companies

  • SillaJen, Inc. : Pexa-Vec

  • Candel Therapeutics: CAN-2409

  • CG Oncology: Virogin Biotech

And many others

Table of Contents

1 Introduction

2 Executive Summary

3 Oncolytic Virus : Overview

3.1Introduction of Oncolytic virus

3.2Different types of Oncolytic virus

3.3Mode of action of Oncolytic viruses

3.4Application of Oncolytic viruses

4 Oncolytic Virus Pipeline Therapeutics

4.1Comparative Analysis

5 Oncolytic Virus Therapeutic Assessment

5.1Assessment by Product Type

5.2Assessment by Stage and Product Type

5.3Assessment by Route of Administration

5.4Assessment by Stage and Route of Administration

5.5Assessment by Molecule Type

5.6Assessment by Stage and Molecule Type

6 Oncolytic Virus – DelveInsight’s Analytical Perspective

7 SillaJen, Inc.

7.1Company overview

7.2Product in development

8 Pexa-Vec : SillaJen, Inc.

8.1Product Description

8.2Research and Development

8.3Product Development Activities

Drug profiles in the detailed report…..

9Candel Therapeutics

9.1Company overview

9.2Product in development

10 CAN-2409: Candel Therapeutics

10.1Product Description

10.2Research and Development

Drug profiles in the detailed report…..

11 CG Oncology

11.1Company overview

11.2Product in development

12 CG0070: CG Oncology

12.1Product Description

12.2Research and Development

12.3Product Development Activities

Drug profiles in the detailed report…..

13 Inactive Products

13.1Comparative Analysis

Oncolytic Virus Key Companies

Oncolytic Virus Key Products

Oncolytic Virus Unmet Needs

Oncolytic Virus Market Drivers and Barriers

Oncolytic Virus Future Perspectives and Conclusion

Oncolytic Virus Analyst Views

Oncolytic Virus Key Companies

Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services